IL326572A - נוגדנים המכוונים ל rankl ולסקלרוסטין ושימושיהם - Google Patents

נוגדנים המכוונים ל rankl ולסקלרוסטין ושימושיהם

Info

Publication number
IL326572A
IL326572A IL326572A IL32657226A IL326572A IL 326572 A IL326572 A IL 326572A IL 326572 A IL326572 A IL 326572A IL 32657226 A IL32657226 A IL 32657226A IL 326572 A IL326572 A IL 326572A
Authority
IL
Israel
Prior art keywords
sclerostin
antibodies targeting
targeting rankl
rankl
antibodies
Prior art date
Application number
IL326572A
Other languages
English (en)
Inventor
Ho CHONG Chi
On Leung Shui
Sum CHIU Pang
Original Assignee
Sinomab Bioscience Ltd
Ho CHONG Chi
On Leung Shui
Sum CHIU Pang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinomab Bioscience Ltd, Ho CHONG Chi, On Leung Shui, Sum CHIU Pang filed Critical Sinomab Bioscience Ltd
Publication of IL326572A publication Critical patent/IL326572A/he

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL326572A 2023-08-17 2024-08-16 נוגדנים המכוונים ל rankl ולסקלרוסטין ושימושיהם IL326572A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363520102P 2023-08-17 2023-08-17
PCT/CN2024/112831 WO2025036493A1 (en) 2023-08-17 2024-08-16 Antibodies targeting rankl and sclerostin and uses thereof

Publications (1)

Publication Number Publication Date
IL326572A true IL326572A (he) 2026-04-01

Family

ID=94632238

Family Applications (1)

Application Number Title Priority Date Filing Date
IL326572A IL326572A (he) 2023-08-17 2024-08-16 נוגדנים המכוונים ל rankl ולסקלרוסטין ושימושיהם

Country Status (5)

Country Link
CN (1) CN121752600A (he)
AU (1) AU2024324084A1 (he)
IL (1) IL326572A (he)
MX (1) MX2026001718A (he)
WO (1) WO2025036493A1 (he)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2460828A3 (en) * 2006-11-10 2012-08-08 UCB Pharma, S.A. Antibodies and diagnostics
EA201391248A1 (ru) * 2011-03-01 2014-05-30 Эмджен Инк. Биспецифические связывающие агенты
MA41142A (fr) * 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
US10961305B2 (en) * 2016-12-21 2021-03-30 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
WO2018139623A1 (en) * 2017-01-30 2018-08-02 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use
SI4190355T1 (sl) * 2017-04-28 2025-02-28 Amgen Inc. Formulacije humanih protiteles proti-RANKL in postopki njihove uporabe

Also Published As

Publication number Publication date
CN121752600A (zh) 2026-03-27
MX2026001718A (es) 2026-04-01
WO2025036493A1 (en) 2025-02-20
WO2025036493A9 (en) 2025-04-24
AU2024324084A1 (en) 2026-04-02

Similar Documents

Publication Publication Date Title
EP4010378A4 (en) ANTICCR8 MONOCLONAL ANTIBODIES AND USES THEREOF
EP3906057A4 (en) ANTI-TCR ANTIBODY MOLECULES AND THEIR USES
EP4146704A4 (en) ANTIBODIES DIRECTED AGAINST CLEC12A AND USE THEREOF
EP4058483A4 (en) ANTI-TCR ANTIBODIES MOLECULES AND THEIR USES
WO2009071696A3 (en) Humanized antibody molecules specific for il-31
AU2021369450A1 (en) Antibodies against sars-cov-2 and uses thereof
WO2023014809A9 (en) Cd3 targeting antibodies and uses thereof
IL288753A (he) נוגדנים נגד epcam פעילות על תנאי, מקטעי נוגדן, אימונוצימודים שלהם ושימושים שלהם
EP4274851A4 (en) MONOCLONAL ANTI-GPRC5D ANTIBODIES AND USES THEREOF
IL315828A (he) נוגדנים כנגד sirp-alpha ושימושים בהם
IL326572A (he) נוגדנים המכוונים ל rankl ולסקלרוסטין ושימושיהם
EP4490199A4 (en) MODIFIED ANTIBODIES AND THEIR USES
IL320218A (he) רנ" א מפריע קטן המייעד c3 ושימושים שלו
WO2012106469A3 (en) Methods for treating infections by targeting microbial h2s-producing enzymes
HK40090076A (en) Antibodies targeting clec12a and use thereof
CA3270550A1 (en) Small interfering rna targeting c3 and uses thereof
CA3282247A1 (en) Antibodies targeting liv-1 and uses thereof
CA3286157A1 (en) Antibodies targeting cd3 and uses thereof
WO2021022108A3 (en) CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
AU2021903205A0 (en) Anti-SARS-CoV-2 antibodies and uses thereof I
GB202204884D0 (en) Sirna targeting kcna1
HK40112024A (en) Antibody targeting cd3, multispecific antibody, and uses thereof
AU2021903206A0 (en) Anti-SARS-CoV-2 antibodies and uses thereof II
CA3285181A1 (en) Modified antibodies and uses thereof
HK40118933A (en) Modified antibodies and uses thereof